Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
M Thill, M-O Zahn, A Welt...
https://pubmed.ncbi.nlm.nih.gov/36807725/Actively Recruiting
Led by iOMEDICO AG · Updated on 2026-06-05
6150
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are conducting a national, prospective, longitudinal, multicenter observational study to document detailed information on the treatment and progression of breast cancer in Germany. This study aims to collect uniform data on patient characteristics, molecular diagnostics, treatments, disease course, and patient-reported health-related quality of life over time. The study includes both early and advanced breast cancer patients and seeks to understand common treatment sequences and changes in therapies. Participants are divided into groups based on breast cancer subtype and stage, including HER2-positive, triple negative, and hormone receptor positive HER2-negative types, for both early and advanced breast cancer. Data collection involves recording all systemic treatments, radiotherapies, surgeries, and outcomes during up to five years of follow-up. The study also includes a decentralized biobank and patient-reported outcomes collected through questionnaires. During the study, researchers gather data at the start of treatment and throughout the observation period, including tumor characteristics, previous treatments, comorbidities, and ongoing therapy details. Key outcome measures include treatment reality, best response, progression-free survival, overall survival, disease-free survival, and patient-reported quality of life. Participation involves regular documentation and questionnaires, enabling comprehensive tracking of breast cancer treatment and outcomes over five years.
CONDITIONS
Breast Cancer Registry Platform
L
Lisa Kruggel
U
Ursula Dietrich
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
iOMEDICO AG
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who undergo routine care are observed, with data collected on treatments, surgeries, and outcomes related to breast cancer.
Periodic visits as part of routine clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Have more questions? Get in touch with our team for quick support
M Thill, M-O Zahn, A Welt...
https://pubmed.ncbi.nlm.nih.gov/36807725/Marc Thill, Mark-Oliver Zahn, Anja Welt...
https://pubmed.ncbi.nlm.nih.gov/39707595/Patrick Marschner, Kai Ringwald, Marc Thill...
https://pubmed.ncbi.nlm.nih.gov/41851017/iOMEDICO AG
Lead Sponsor